Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

Similar articles for PubMed (Select 23599045)

1.

The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty.

Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Wettergren A, Svendsen LB, Meisner S, Hovendal C, Vilsbøll T, Knop FK, Holst JJ.

Am J Physiol Gastrointest Liver Physiol. 2013 Jun 15;304(12):G1117-27. doi: 10.1152/ajpgi.00035.2013. Epub 2013 Apr 18.

2.

Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?

Asmar M, Bache M, Knop FK, Madsbad S, Holst JJ.

J Clin Endocrinol Metab. 2010 May;95(5):2367-75. doi: 10.1210/jc.2009-2133. Epub 2010 Mar 1.

PMID:
20194711
3.

Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty.

Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Wettergren A, Svendsen LB, Meisner S, Hovendal C, Knop FK, Vilsbøll T, Holst JJ.

Eur J Endocrinol. 2013 Jul 6;169(2):187-201. doi: 10.1530/EJE-13-0264. Print 2013 Aug.

4.

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH.

Am J Physiol. 1997 Nov;273(5 Pt 1):E981-8.

5.

Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.

Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM.

Am J Clin Nutr. 1998 Sep;68(3):525-30.

7.

Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.

Kielgast U, Holst JJ, Madsbad S.

Diabetes. 2011 May;60(5):1599-607. doi: 10.2337/db10-1790. Epub 2011 Mar 25.

8.

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.

Lee A, Patrick P, Wishart J, Horowitz M, Morley JE.

Diabetes Obes Metab. 2002 Sep;4(5):329-35.

PMID:
12190996
9.

Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats.

Fujiwara K, Gotoh K, Chiba S, Masaki T, Katsuragi I, Kakuma T, Yoshimatsu H.

J Neurochem. 2012 Apr;121(1):66-76. doi: 10.1111/j.1471-4159.2011.07563.x. Epub 2012 Feb 15.

PMID:
22035323
10.

Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.

Lugari R, Dei Cas A, Ugolotti D, Barilli AL, Camellini C, Ganzerla GC, Luciani A, Salerni B, Mittenperger F, Nodari S, Gnudi A, Zandomeneghi R.

Horm Metab Res. 2004 Feb;36(2):111-5.

PMID:
15002062
11.

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.

Meier JJ, Gethmann A, Nauck MA, Götze O, Schmitz F, Deacon CF, Gallwitz B, Schmidt WE, Holst JJ.

Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1118-23. Epub 2006 Jan 10.

12.

The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1.

Hayes MR, Kanoski SE, De Jonghe BC, Leichner TM, Alhadeff AL, Fortin SM, Arnold M, Langhans W, Grill HJ.

Am J Physiol Regul Integr Comp Physiol. 2011 Nov;301(5):R1479-85. doi: 10.1152/ajpregu.00356.2011. Epub 2011 Aug 17.

13.

Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients.

Sonne DP, Hare KJ, Martens P, Rehfeld JF, Holst JJ, Vilsbøll T, Knop FK.

Am J Physiol Gastrointest Liver Physiol. 2013 Feb 15;304(4):G413-9. doi: 10.1152/ajpgi.00435.2012. Epub 2012 Dec 28.

14.

Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus.

Schirra J, Leicht P, Hildebrand P, Beglinger C, Arnold R, Göke B, Katschinski M.

J Endocrinol. 1998 Jan;156(1):177-86.

15.
16.

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans.

Nauck MA, Kemmeries G, Holst JJ, Meier JJ.

Diabetes. 2011 May;60(5):1561-5. doi: 10.2337/db10-0474. Epub 2011 Mar 23.

17.

Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.

Chelikani PK, Haver AC, Reidelberger RD.

Am J Physiol Regul Integr Comp Physiol. 2005 Jun;288(6):R1695-706. Epub 2005 Feb 17.

18.

The vagus is inhibitory of the late postprandial insulin secretion in conscious pigs.

Blat S, Guérin S, Chauvin A, Sève B, Morgan L, Cuber JC, Malbert CH.

Auton Neurosci. 2002 Oct 31;101(1-2):68-77.

PMID:
12462361
19.

Is glucagon-like peptide 1 an incretin hormone?

Nauck MA.

Diabetologia. 1999 Mar;42(3):373-9. Review.

PMID:
10096792
20.

No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man.

Long SJ, Sutton JA, Amaee WB, Giouvanoudi A, Spyrou NM, Rogers PJ, Morgan LM.

Br J Nutr. 1999 Apr;81(4):273-9.

PMID:
10999014
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk